



IHF MEMBERS SURVEY - Molecularly Targeted Therapies Survey Report

A survey on “Molecularly Targeted Therapies” was sent to IHF Full and Associate Members.

The total number of respondents was 11 from the following Countries: Argentina; Brazil; Finland; France; Germany; Iran; Kingdom of Bahrain; Kuwait; Portugal; Switzerland; United Arab Emirates.

Among the 11 surveyed countries, 8 answered positively to the question “Do you have Molecularly Targeted Therapies in your Country?” Responses from Brazil and the United Arab Emirates were “do not know”. The Kingdom of Bahrain was the only country without molecularly targeted therapies.



A great number of anti-cancer therapies drugs are available. Three drugs were selected for this survey: *Jevtana (Cabazitaxel – Sanofi)*; *Yervoy (Ipilimumab – BMS)*; *Yondélis (Trabectedine – Pharmamar)*. Three (3) of the 11 countries surveyed did not respond to the question related to the use of these drugs.

Among the respondents, 6 have the three drugs. In Iran both Jevtana (Cabazitaxel – Sanofi) and Yondélis


(Trabectedine – Pharmamar) are used, whilst only Yondélis (Trabectedine – Pharmamar) is available in Kuwait.

These drugs are fully funded for 62.5% of respondents; in Portugal drugs are included in hospital budgets. In Iran and in France the drugs are partially funded.

The following table shows the price of the three molecules in the different countries. Details are also provided about how expenses for drugs are funded.

Argentina (http://web.alfabeta.net/mapa.xtp)				
	Price	Unit of Measurement	Reimbursement	Who pays?
Jevtana	38716.30€ (46878.14\$)	60 mg/1.5 ml	Full	Public and Private Insurance
Yervoy	Not provided	50 mg	Full	Public and Private Insurance
Yondélis	Not provided	0.25 mg	Full	Public and Private Insurance
Finland (http://asiointi.kela.fi/laakekys_app/LaakekysApplication)				
Jevtana	5531.86 €	1 treatment	Full	Included in hospital budget and Social Insurance Institution in Finland
Yervoy	5388.96 €	10 ml	Full	Included in hospital budget and Social Insurance Institution in Finland
Yondélis	708.88 €	0.25 mg	Full	Included in hospital budget and Social Insurance Institution in Finland
France (http://www.atih.sante.fr/index.php?id=0001000029FF)				
Jevtana	Not provided		Partial	Public Insurance and Included in Hospital Budget
Yervoy	Not provided	10 ml	Partial	Public Insurance and Included in Hospital Budget
Yondélis	208.09€	0.25 mg	Partial	Public Insurance and Included in Hospital Budget
Germany (http://www.akdae.de/suche/index.html?q=Suche&ps=5)				
Jevtana	21302.10 €	6 treatments	Full	Public Insurance
Yervoy	87182.26 €	4 doses	Full	Public Insurance
Yondélis	4801.70 €	per cycle	Full	Public Insurance
Iran				
Jevtana	Not provided		Partial	Private Insurance
Yondélis	Not provided		Partial	Private Insurance
Kuwait				
Yondélis	Not provided		Full	Government Budget
Portugal (http://www.infarmed.pt/infomed/pesquisa.php)				
Jevtana	Not provided	1 unit (1.5 ml)		Included in hospital budget
Yervoy	Not provided	10 ml		Included in hospital budget
Yondélis	Not provided	0.25 mg		Included in hospital budget
Switzerland (http://bag.e-mediat.net/SL2007.Web.External/ShowPreparations.aspx)				
Jevtana	In evaluation status			
Yervoy	4599.83€ (5524.75 CHF)	50 mg	Full	Public Insurance and Included in Hospital Budget
Yondélis	748.75€ (899.30 CHF)	0.25 mg	Full	Public Insurance and Included in Hospital Budget

Eight of the eleven countries surveyed responded to the question on the sources of funding of the drugs. This information is shown in the table below:



The overall picture is that, in the majority of cases, the sources of funding of the drugs are either through public insurance or integration in hospital budgets. Other funding sources are available in Kuwait and Finland. In Kuwait payment is through government budget whilst in Finland, it is through a combination of hospital budgets and social insurance scheme.

